Current Issue

View Larger Image

Past Issues Adlink Subscription Visit Our Publisher

ADVERTISEMENT



Top Keywords




Interactive Biosoftware

click to enlarge

Mutation Dx Software

Alamut® 2.0 is a decision-support software application for medical molecular genetics, dedicated to mutation diagnostics. By integrating gene annotations from multiple data sources and in silico prediction tools in a consistent environment, the software helps increase quality and productivity of variants assessment. This latest version includes a number of new features and user-defined custom tools. Alamut now supports the GRCh37 (hg19) genome assembly as well as RefSeqGene and Locus Reference Genomic sequences. It integrates the Human Gene Mutation Database, available to HGMD® Professional subscribers. It provides automatic computation of missense predictions with PolyPhen-2, SIFT, and Align GVGD. The splicing prediction toolset has been enriched with the Human Splicing Finder prediction algorithm. A new conservation score across vertebrate genomes, phyloP, has also been added.

Related To This Company

Products

Related content

Webinars

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe
e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
Confirm Email
First Name
Last Name
Organization
E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll